RxDoctor Payments Data

Mark Holmes, OD

Optometrist · West Des Moines, IANPI 1306838115

Payments from drug & device makers

$1,558in general payments, 2019–2025

Across 26 payments — averaging $59.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$435
  • Amgen$233
  • AbbVie$137
  • Shire North American Group Inc$125
  • Kala Pharmaceuticals, Inc.$124
  • Aerie Pharmaceuticals, Inc.$122
  • plus $383 from 5 others

What the payments were for

  • Food & beverage$1,558100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,558 in reported general payments places this provider in the 80th percentile of 559 optometrist providers in Iowa.

See all optometrist providers in Iowa

Medicare billing

Part B allowed, 2024
$192,013
Medicare patients
1,321
Services billed
2,046

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine84$86,802
XiidraLifitegrast24$30,497
LumiganBimatoprost42$21,179
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol27$6,053
Latanoprost656$5,603
Travoprost35$5,407
Cyclosporine12$5,231
Fluorometholone57$4,929
Alphagan PBrimonidine Tartrate15$3,628
CombiganBrimonidine Tartrate/Timolol13$3,394
Brimonidine Tartrate34$1,849
Prednisolone Acetate42$1,560
Timolol Maleate222$1,463
Tobramycin-DexamethasoneTobramycin/Dexamethasone12$727
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat37$596

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$137$115,003154 claims
Bausch & Lomb Americas Inc.Xiidra$106$30,49724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 559 optometrist providers in Iowa.

Other optometrist in West Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →